DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Minority Health and Health Disparities; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Council on Minority Health and Health Disparities.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council on Minority Health and Health Disparities.

Date: June 12, 2012.

Closed: 8:00 a.m. to 9:30 a.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: National Institutes of Health, National Institute on Minority Health and Health Disparities, 6707 Democracy Blvd., Rm. 849, Bethesda, MD 20892.


Anna P. Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–11507 Filed 5–10–12; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel, NIBIB P41 Site Visit (2012/10).

Date: July 25–27, 2012.

Time: 6:00 p.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites Vanderbilt, 1811 Broadway, Nashville, TN 37203.

Contact Person: Ruth Grossman, DDS, Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, 6707 Democracy Boulevard, Room 960, Bethesda, MD 20892, 301–496–8775, grossmanrs@mail.nih.gov.


Anna P. Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–11507 Filed 5–10–12; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Announcement of National Eye Institute Participation in PA–11–347, “NINDS SBIR Technology Transfer (SBIR–TT [R43/R44])”

This notice is intended to inform potential applicants that the National Eye Institute (NEI) is participating in PA–11–347, “NINDS SBIR Technology Transfer (SBIR–TT [R43/R44]).” The NEI seeks SBIR applications for projects to transfer technologies out of the NIH intramural research labs into the private sector that address mechanisms, diseases, or disorders within the NEI mission.

Any project that fits within the NEI mission and relies on the use of an NIH intramural technology is eligible for this award. Please see the NEI technology transfer Web site for more details on NEI licensing opportunities: http://www.nei.nih.gov/resources/technologytransfer.aspx.

For a complete listing of NIH intramural technologies which are available, please see NIH Office of Technology Transfer at: http://www.ott.nih.gov/Technologies/AbsSearchBox.aspx.

The NEI Division of Intramural Research performs high quality and innovative research in a variety of basic, translational, and clinical areas,
including imaging, diagnostics, regenerative medicine, genetics/genomics, developmental biology, cellular and gene therapy, and cell and molecular biology related to eye health and eye disease treatments. For more information about the research and investigators in the NEI Division of Intramural Research, please see: http://www.nei.nih.gov/intramural/.

An NEI intramural investigator may provide assistance in a collaborative manner by providing technology, reagents and/or discussions during the SBIR award period; however, no SBIR funds are allowed to go to the NIH intramural investigator or the NIH intramural program.

All other aspects of the Funding Opportunity Announcement (FOA) remain unchanged.

Inquiries:
SBIR contact: Jerome Wujek, Ph.D., 5635 Fishers Lane; MSC 9300, Bethesda, MD 20892, (301) 451–2020, wujekjer@nei.nih.gov.

License contact: Alan E. Hubbs, Ph.D., 6120 Executive Blvd., Bethesda, MD 20892, (301) 594–4263, hubbas@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)


David Whitmer,
Executive Officer, NEI, National Institutes of Health.

[FR Doc. 2012–15152 Filed 5–10–12; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Request for Information Regarding the NIH-Industry Program To Discover New Therapeutic Uses for Existing Molecules

SUMMARY: As part of a larger initiative to help reengineer the process of translating scientific discoveries into new therapies, the recently established National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) will be launching a new collaborative program to support the exploration of promising drug candidates (compounds and biologics) across a broad range of human diseases. As an initial effort, the program will focus on discovering new therapeutic uses of existing molecules (Therapeutics Discovery).

The NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules is designed to be carried out through collaborations between pharmaceutical companies and the biomedical research community. The Program will match drug candidates and associated data from participating companies with the best ideas for new therapeutic uses put forward by the biomedical research community.

NCATS will be initiating this innovative concept as a limited pilot Program. If the pilot is successful, and depending on the level of interest and available funds, the Program may be expanded. To gauge the breadth and depth of potential interest in the Program and to obtain stakeholder input and perspectives on its novel features, NCATS is seeking input from the biomedical research community, prospective industry collaborators, and other members of the public on all aspects of the Program and more broadly on how the government can partner with the private sector in this area.


FOR FURTHER INFORMATION CONTACT: Questions may be submitted electronically to Therapeutics.Discovery@nih.gov. For additional information, please contact Dr. Heng Xie, NCATS, at XieHe@mail.nih.gov or 301–443–8063.

SUPPLEMENTARY INFORMATION:

Background
On December 23, 2011, Congress created NCATS, (Pub. L. 112–74 passed December 23, 2011, amending the Public Health Service Act, 42 U.S.C. 287). One aspect of the NCATS mission focuses on developing innovative strategies, methods, and tools to reduce or eliminate barriers to drug and diagnostic development. By developing new methods that can be adopted across the entire medical product development sector, NCATS will enhance the capabilities of other sectors to bring safe and effective products to patients.

One of the strategies that NCATS will be pursuing is to advance research and development (R&D) efforts to find uses for therapeutics different from those for which they were originally developed (Therapeutics Discovery). Many discontinued compounds and biologics that have already been tested in human subjects may have promising applications for other indications and many approved drugs may be put to new uses. Harnessing previous R&D efforts and building on data already gathered may be a way to speed the testing of new clinical hypotheses and bring forward new treatments for a range of human diseases. Along with opportunities, however, there are also scientific, economic, and administrative challenges that need to be addressed. These were explored in an April 2011 Roundtable with senior leaders and experts from the pharmaceutical industry, government, academia, and the non-profit sector (http://www.ncats.nih.gov/files/exploring_new_uses_for_abandoned_and_approved_therapeutics.pdf.pdf). Some of the challenges identified at the Roundtable include: Resource implications (the time and resources for a pharmaceutical company to maintain, update, and organize their therapeutics libraries for investigating new therapeutic uses prior (drug rescue) or subsequent to (drug repurposing) FDA approval; patent considerations (off-patent or drugs whose patents are close to expiring may not be attractive to industry because the financial return and market incentives for the product may be limited); and transactional hurdles related to developing, negotiating and implementing appropriate legal agreements among the parties, including addressing such concerns as intellectual property rights and liability. The Roundtable participants concluded that because the private sector holds a substantial portion of the requisite assets, data, and knowledge and the public sector has new ideas and the wherewithal to advance new applications, public-private collaborations are central to rescue and repurposing efforts. Streamlining the initiation and execution of such partnerships will help promote collaboration, leverage the strengths of both sectors, and facilitate the formation of partnerships that are so critical to success.

NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules

The NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules Program is designed to be carried out through collaborations between pharmaceutical companies and investigators from the biomedical research community. The Program will match drug candidates and associated data from participating companies with the best ideas for new therapeutic uses put forward by the biomedical research community. Funded investigators will